These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32576154)

  • 1. Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study.
    Lee EG; Min J; Kang JY; Kim SK; Kim JW; Kim YH; Yoon HK; Lee SH; Kim HW; Kim JS
    BMC Infect Dis; 2020 Jun; 20(1):446. PubMed ID: 32576154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
    Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
    J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
    Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
    BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk assessment and transmission of fluoroquinolone resistance in drug-resistant pulmonary tuberculosis: a retrospective genomic epidemiology study.
    Nehru VJ; Jose Vandakunnel M; Brammacharry U; Ramachandra V; Pradhabane G; Mani BR; Vn AD; Muthaiah M
    Sci Rep; 2024 Aug; 14(1):19719. PubMed ID: 39181942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
    J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of Mycobacterium tuberculosis Complex Strains Isolated from the Samples of Patients Living in Northern Syria].
    Gazel D; Çeylan K; Çalışkantürk G; Karslıgil T
    Mikrobiyol Bul; 2023 Jul; 57(3):444-453. PubMed ID: 37462307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen.
    Lempens P; Decroo T; Aung KJM; Hossain MA; Rigouts L; Meehan CJ; Van Deun A; de Jong BC
    Int J Infect Dis; 2020 Nov; 100():357-365. PubMed ID: 32829049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia.
    Hamusse SD; Teshome D; Hussen MS; Demissie M; Lindtjørn B
    BMC Public Health; 2016 Jul; 16():593. PubMed ID: 27430266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017.
    Glasauer S; Altmann D; Hauer B; Brodhun B; Haas W; Perumal N
    PLoS One; 2019; 14(6):e0217597. PubMed ID: 31188848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
    Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
    BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest Ethiopia.
    Adane K; Ameni G; Bekele S; Abebe M; Aseffa A
    BMC Public Health; 2015 Jun; 15():572. PubMed ID: 26092570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and factors associated with multidrug-resistant tuberculosis in South India.
    Shivekar SS; Kaliaperumal V; Brammacharry U; Sakkaravarthy A; Raj CKV; Alagappan C; Muthaiah M
    Sci Rep; 2020 Oct; 10(1):17552. PubMed ID: 33067551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line Drug Resistance Characterization in
    Sethi S; Agarwal P; Khaneja R; Kumar N; Kumar N; Chandna J; Aggarwal AN; Yadav R
    J Epidemiol Glob Health; 2020 Mar; 10(1):42-45. PubMed ID: 32175709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
    Walsh KF; Souroutzidis A; Vilbrun SC; Peeples M; Joissaint G; Delva S; Widmann P; Royal G; Pry J; Bang H; Pape JW; Koenig SP
    Am J Trop Med Hyg; 2019 Feb; 100(2):392-398. PubMed ID: 30594266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiological profile of patients with rifampicin-resistant tuberculosis: an analysis of the Uganda National Tuberculosis Reference Laboratory Surveillance Data, 2014-2018.
    Bahizi G; Majwala RK; Kisaka S; Nyombi A; Musisi K; Kwesiga B; Bulage L; Ario AR; Turyahabwe S
    Antimicrob Resist Infect Control; 2021 May; 10(1):76. PubMed ID: 33964986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.